Genmab A/S
Genmab's GHG Emissions Data Preview
In 2024, Genmab completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Genmab has also provided a category-level breakdown for 6 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  b | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy/Paste is a PRO feature.  a | 0000000 | Copy/Paste is a PRO feature.  b | 0000000 |
Location-Based | Copy/Paste is a PRO feature.  a | 0000000 | Copy/Paste is a PRO feature.  | 0000000 |
Total Scope 3 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  a | 0000000 | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0000000 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  b | 0000000 |
a
a
a
a
a
aVerified Sources Behind Genmab’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Genmab’s data sources below and access millions more through our Disclosure Search.
Insights into Genmab's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Genmab amounted to 3,239 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Genmab increased by 113.51%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
Genmab's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Genmab's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Genmab were 534 metric tons of CO₂ equivalent (tCO₂e).a
Has Genmab reduced its Scope 1 emissions over time?
Since 2021, Genmab's Scope 1 emissions have increased by 56.51%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Genmab's Scope 1 emissions increased by 68.45%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
What are Genmab's Scope 2 emissions?
In 2024, Genmab reported Scope 2 greenhouse gas (GHG) emissions of 1,163 tCO₂e using the market-based method and 2,705 tCO₂e using the location-based method.a
Has Genmab reduced its Scope 2 emissions over time?
Compared to the previous year (2023), Genmab's Scope 2 emissions (Location-Based) rose by 125.42% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
What methodology does Genmab use for Scope 2 reporting?
In 2024, Genmab reported its Scope 2 emissions using the market-based method and using the location-based method.a
Genmab's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Genmab's Value Chain Emissions
In 2024, Genmab reported 187,976 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Genmab includes a breakdown across 6 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
Genmab's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Genmab's Scope 3 emissions?
In 2024, Genmab reported total Scope 3 emissions of 187,976 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Genmab's Scope 3 emissions increased by 24.56%, suggesting that the company faced challenges in reducing emissions across its value chain.a
What categories of Scope 3 emissions does Genmab disclose?
In 2024, Genmab reported emissions for 6 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Genmab's Scope 3 emissions?
In 2024, the largest contributors to Genmab's Scope 3 emissions were:a
- Purchased Goods and Services (Cat. 1): 164,449 tCO₂e (87.48%)
- Business Travel (Cat. 6): 10,559 tCO₂e (5.62%)
- Capital Goods (Cat. 2): 5,519 tCO₂e (2.94%)
Genmab's Scope 3 Emissions by Categories
Insights into Genmab’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Genmab reported Scope 1 greenhouse gas (GHG) emissions of 534 tCO₂e and total revenues of USD 3,003 millions. This translates into an emissions intensity of 0.18 tCO₂e per millions USD.a
Genmab's Scope 1 Emissions Intensity Compared to Peers
How does Genmab's GHG emissions intensity compare to its peers?
In 2024, Genmab reported a Scope 1 emissions intensity of 0.18 tCO₂e per millions USD. Compared to the peer group median of 7.24, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
Where does Genmab rank on GHG emissions intensity within its industry?
In 2024, Genmab ranked 4 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Genmab among the top performers, with one of the lowest emissions intensities relative to peers.a
Insights into Genmab's Total Carbon Footprint
In 2024, Genmab reported a total carbon footprint of 191,215 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 25.45% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Genmab's total carbon footprint was Scope 3 emissions, accounting for 98.31% of the company's total carbon footprint, followed by Scope 2 emissions at 1.41%.a